Acute emesis: moderately emetogenic chemotherapy

Jørn Herrstedt, Bernardo Rapoport, David Warr, Fausto Roila, Emilio Bria, Cynthia Rittenberg, Paul J Hesketh

Research output: Contribution to journalJournal articleResearchpeer-review

Abstract

This paper is a review of the recommendations for the prophylaxis of acute emesis induced by moderately emetogenic chemotherapy as concluded at the third Perugia Consensus Conference, which took place in June 2009. The review will focus on new studies appearing since the Second consensus conference in April 2004. The following issues will be addressed: dose and schedule of antiemetics, different groups of antiemetics such as corticosteroids, serotonin(3) receptor antagonists, dopamine(2) receptor antagonists, and neurokinin(1) receptor antagonists. Furthermore, antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy will be reviewed. Consensus statements are given, including optimal dose and schedule of serotonin(3) receptor antagonists, dexamethasone, and neurokinin(1) receptor antagonists. The most significant recommendations (and changes since the 2004 version of the guidelines) are as follows: the best prophylaxis in patients receiving moderately emetogenic chemotherapy (not including a combination of an anthracycline plus cyclophosphamide) is the combination of palonosetron and dexamethasone on the day of chemotherapy, followed by dexamethasone on days 2-3. In patients receiving a combination of an anthracycline plus cyclophosphamide, a combination of a serotonin(3) receptor antagonist plus dexamethasone, plus the neurokinin(1) receptor antagonist aprepitant on the day of chemotherapy, followed by aprepitant days 2-3, is recommended.
Original languageEnglish
JournalSupportive Care in Cancer
Volume19
Issue number1
Pages (from-to)S15-23
ISSN0941-4355
DOIs
Publication statusPublished - 2011

Fingerprint

aprepitant
Serotonin Antagonists
Dopamine Antagonists
Adrenal Cortex Hormones
Guidelines

Cite this

Herrstedt, J., Rapoport, B., Warr, D., Roila, F., Bria, E., Rittenberg, C., & Hesketh, P. J. (2011). Acute emesis: moderately emetogenic chemotherapy. Supportive Care in Cancer, 19(1), S15-23. https://doi.org/10.1007/s00520-010-0951-5
Herrstedt, Jørn ; Rapoport, Bernardo ; Warr, David ; Roila, Fausto ; Bria, Emilio ; Rittenberg, Cynthia ; Hesketh, Paul J. / Acute emesis: moderately emetogenic chemotherapy. In: Supportive Care in Cancer. 2011 ; Vol. 19, No. 1. pp. S15-23.
@article{fce13caf38014a2da2fb5539a0f4ce3b,
title = "Acute emesis: moderately emetogenic chemotherapy",
abstract = "This paper is a review of the recommendations for the prophylaxis of acute emesis induced by moderately emetogenic chemotherapy as concluded at the third Perugia Consensus Conference, which took place in June 2009. The review will focus on new studies appearing since the Second consensus conference in April 2004. The following issues will be addressed: dose and schedule of antiemetics, different groups of antiemetics such as corticosteroids, serotonin(3) receptor antagonists, dopamine(2) receptor antagonists, and neurokinin(1) receptor antagonists. Furthermore, antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy will be reviewed. Consensus statements are given, including optimal dose and schedule of serotonin(3) receptor antagonists, dexamethasone, and neurokinin(1) receptor antagonists. The most significant recommendations (and changes since the 2004 version of the guidelines) are as follows: the best prophylaxis in patients receiving moderately emetogenic chemotherapy (not including a combination of an anthracycline plus cyclophosphamide) is the combination of palonosetron and dexamethasone on the day of chemotherapy, followed by dexamethasone on days 2-3. In patients receiving a combination of an anthracycline plus cyclophosphamide, a combination of a serotonin(3) receptor antagonist plus dexamethasone, plus the neurokinin(1) receptor antagonist aprepitant on the day of chemotherapy, followed by aprepitant days 2-3, is recommended.",
author = "J{\o}rn Herrstedt and Bernardo Rapoport and David Warr and Fausto Roila and Emilio Bria and Cynthia Rittenberg and Hesketh, {Paul J}",
note = "Accepted: 2 July 2010 Published online: 2 August 2010",
year = "2011",
doi = "10.1007/s00520-010-0951-5",
language = "English",
volume = "19",
pages = "S15--23",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Heinemann",
number = "1",

}

Herrstedt, J, Rapoport, B, Warr, D, Roila, F, Bria, E, Rittenberg, C & Hesketh, PJ 2011, 'Acute emesis: moderately emetogenic chemotherapy', Supportive Care in Cancer, vol. 19, no. 1, pp. S15-23. https://doi.org/10.1007/s00520-010-0951-5

Acute emesis: moderately emetogenic chemotherapy. / Herrstedt, Jørn; Rapoport, Bernardo; Warr, David; Roila, Fausto; Bria, Emilio; Rittenberg, Cynthia; Hesketh, Paul J.

In: Supportive Care in Cancer, Vol. 19, No. 1, 2011, p. S15-23.

Research output: Contribution to journalJournal articleResearchpeer-review

TY - JOUR

T1 - Acute emesis: moderately emetogenic chemotherapy

AU - Herrstedt, Jørn

AU - Rapoport, Bernardo

AU - Warr, David

AU - Roila, Fausto

AU - Bria, Emilio

AU - Rittenberg, Cynthia

AU - Hesketh, Paul J

N1 - Accepted: 2 July 2010 Published online: 2 August 2010

PY - 2011

Y1 - 2011

N2 - This paper is a review of the recommendations for the prophylaxis of acute emesis induced by moderately emetogenic chemotherapy as concluded at the third Perugia Consensus Conference, which took place in June 2009. The review will focus on new studies appearing since the Second consensus conference in April 2004. The following issues will be addressed: dose and schedule of antiemetics, different groups of antiemetics such as corticosteroids, serotonin(3) receptor antagonists, dopamine(2) receptor antagonists, and neurokinin(1) receptor antagonists. Furthermore, antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy will be reviewed. Consensus statements are given, including optimal dose and schedule of serotonin(3) receptor antagonists, dexamethasone, and neurokinin(1) receptor antagonists. The most significant recommendations (and changes since the 2004 version of the guidelines) are as follows: the best prophylaxis in patients receiving moderately emetogenic chemotherapy (not including a combination of an anthracycline plus cyclophosphamide) is the combination of palonosetron and dexamethasone on the day of chemotherapy, followed by dexamethasone on days 2-3. In patients receiving a combination of an anthracycline plus cyclophosphamide, a combination of a serotonin(3) receptor antagonist plus dexamethasone, plus the neurokinin(1) receptor antagonist aprepitant on the day of chemotherapy, followed by aprepitant days 2-3, is recommended.

AB - This paper is a review of the recommendations for the prophylaxis of acute emesis induced by moderately emetogenic chemotherapy as concluded at the third Perugia Consensus Conference, which took place in June 2009. The review will focus on new studies appearing since the Second consensus conference in April 2004. The following issues will be addressed: dose and schedule of antiemetics, different groups of antiemetics such as corticosteroids, serotonin(3) receptor antagonists, dopamine(2) receptor antagonists, and neurokinin(1) receptor antagonists. Furthermore, antiemetic prophylaxis in patients receiving multiple cycles of moderately emetogenic chemotherapy will be reviewed. Consensus statements are given, including optimal dose and schedule of serotonin(3) receptor antagonists, dexamethasone, and neurokinin(1) receptor antagonists. The most significant recommendations (and changes since the 2004 version of the guidelines) are as follows: the best prophylaxis in patients receiving moderately emetogenic chemotherapy (not including a combination of an anthracycline plus cyclophosphamide) is the combination of palonosetron and dexamethasone on the day of chemotherapy, followed by dexamethasone on days 2-3. In patients receiving a combination of an anthracycline plus cyclophosphamide, a combination of a serotonin(3) receptor antagonist plus dexamethasone, plus the neurokinin(1) receptor antagonist aprepitant on the day of chemotherapy, followed by aprepitant days 2-3, is recommended.

U2 - 10.1007/s00520-010-0951-5

DO - 10.1007/s00520-010-0951-5

M3 - Journal article

C2 - 20680356

VL - 19

SP - S15-23

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - 1

ER -

Herrstedt J, Rapoport B, Warr D, Roila F, Bria E, Rittenberg C et al. Acute emesis: moderately emetogenic chemotherapy. Supportive Care in Cancer. 2011;19(1):S15-23. https://doi.org/10.1007/s00520-010-0951-5